Compare Revvity Inc (RVTY) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Sea Limited — how do they compare? Revvity Inc trades at $154.1 (market cap $16.98B), while Sea Limited trades at $95.7 (market cap $56.89B). The key difference: Sea Limited is far larger — about 3.4× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while Sea Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Sea Limited for 102 Days on average.
| RVTY | SE | |
|---|---|---|
Market Cap | $16.98B | $56.89B |
Volume | 1,456,900 | 5,359,457 |
Sector | Health | Consumer Cyclical |
52-Week High | $157.36 | $188.00 |
52-Week Low | $82.26 | $78.16 |
Typical Hold Time | 12 Days | 102 Days |
Enterprise Value | $19.30B | $51.92B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Sea Limited (SE) trades at $95.25, down 0.62% with a bearish technical signal. The company shows strong fundamental improvement with revenue growing from $12.4B in 2022 to $22.9B in 2025, achieving profitability with net income of $1.58B. Analyst consensus remains strongly bullish with 70% buy ratings and a $153.67 price target, though recent insider selling and technical weakness create near-term headwinds. Operating cash flow has turned positive at $5.02B, supporting the company's growth trajectory.
Sea Limited presents a compelling growth story with improving profitability and strong analyst support, though technical weakness and insider selling warrant caution. The stock trades at a discount to analyst targets with solid fundamentals, but investors should monitor execution risks in competitive e-commerce and digital entertainment markets. The current price level near support at $91-92 offers potential entry for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
